Physiologically ‐based pharmacokinetic modelling to predict oprozomib CYP3A drug‐drug interaction potential in patients with advanced malignancies

ConclusionsThese results indicate oprozomib has a low potential to inhibit the metabolism of CYP3A4 substrates in humans. The study shows that cultured human hepatocytes are a more reliable system for DDI prediction than human liver microsomes for studying this class of compounds. Developing a PBPK model prior to a clinical DDI study has been valuable in supporting clinical development of oprozomib.

Source: British Journal of Clinical Pharmacology - November 14, 2018 Category: Drugs & Pharmacology Authors: Ying Ou, Yang Xu, Lia Gore, R. Donald Harvey, Alain Mita, Kyriakos P. Papadopoulos, Zhengping Wang, Richard E. Cutler, Dawn E. Pinchasik, Apostolia M. Tsimberidou Tags: ORIGINAL ARTICLE Source Type: research